Expression of human prostate-specific antigen (PSA) in a mouse tumor cell line reduces tumorigenicity and elicits PSA-specific cytotoxic T lymphocytes

Cancer Immunology Immunotherapy

Volumn 42, Issue 6, 1996, Pages 362-368

  Wei, Chungwen ^a   Storozynsky, Eugene ^b   McAdam, Alexander J ^b,c   Yeh, Kun Yun ^b   Tilton, Brian R ^b   Willis, Richard A ^b   Barth, Richard K ^a,b   Looney, R John ^b   Lord, Edith M ^a,b   Frelinger, John G ^a,b  

^a UNIVERSITY OF ROCHESTER   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Immunotherapy; Prostate adenocarcinoma; Prostate specific antigen; T cell mediated immunity

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CARCINOGENICITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HUMAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH;

ANIMALS; EPITOPES; HUMANS; LUNG NEOPLASMS; MALE; MAST-CELL SARCOMA; MICE; MICE, INBRED BALB C; MICE, INBRED DBA; NEOPLASMS, EXPERIMENTAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 9544254883     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050295     Document Type: Article

References (44)

1. Bahler DW, Lord EM (1985) Dimethyl sulfoxide induces expression of H-2 antigens on mouse lung carcinoma cells, J Immunol 134:2790
2. Bakker AB, Schreurs MW, Boer AJ de, Kawakami Y, Rosenberg SA, Adema GJ, Figdor CG (1994) Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med 179:1005
3. Blieden TM, McAdam AJ, Frelinger JG, Lord EM (1991) Mechanism of cytolytic T lymphocyte killing of a low class I-expressing tumor. J Immunol 147:1433
4. Boring CC, Squires TS, Tong T (1991) Cancer statistics. CA Cancer J Clin 41:19
5. Boring CC, Squires TS, Tong T (1993) Cancer statistics. CA Cancer J Clin 43:7
6. Brawer MK (1995) How to use prostate-specific antigen in the early detection or screening for prostatic carcinoma. CA Cancer J Clin 45:148
7. Brichard V, Van Pel A, Wolfel T, Wolfel C, De Plaen E, Lethe B, Coulie P, Boon T (1993) The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 178:489
8. Catalona WJ (1995) Surgical management of prostate cancer. Cancer 75:1903
9. Chu TM, Kuriyama M, Johnson E, Papsidero LD, Killian CS, Murphy GP, Wang MC (1984) Circulating antibody to prostate antigen in patients with prostate cancer. Transplant Proc 16:481
10. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ (1989) A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321:419
11. Guo Y, Pili R, Passaniti A (1994) Regulation of prostate-specific antigen gene expression in LNCaP human prostatic carcinoma cells by growth, dihydrotestosterone, and extracellular matrix. Prostate 24:1
12. Hodge JW, Schlom J, Donohue SJ, Tomaszewski JE, Wheeler CW, Levine BS, Gritz L, Panicali D, Kantor JA (1995) A recombinant vaccinia virus expressing human prostate-specific antigen (PSA): safety and immunogenicity in a non-human primate. Int J Cancer 63:231
13. Isaacs JT (1982) Hormonally responsive versus unresponsive progression of prostatic cancer to antiandrogen therapy as studied with the Dunning R-3327-AT and -G rat adenocarcinomas. Cancer Res 42:5010
14. Isaacs JT (1989) Relationship between tumor size and curability of prostatic cancer by combined chemo-hormonal therapy in rats. Cancer Res 49:6290
15. Isaacs JT (1994) Role of androgens in prostatic cancer. Vitam Horm 49:433
16. Isaacs JT, Hukku B (1988) Nonrandom involvement of chromosome 4 in the progression of rat prostatic cancer. Prostate 13:165
17. Karr JF, Kantor JA, Hand PH, Eggensperger DL, Schlom J (1995) The presence of prostate-specific antigen-related genes in primates and the expression of recombinant human prostate-specific antigen in a transfected murine cell line. Cancer Res 55:2455
18. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Rivoltini L, Topalian SL, Miki T, Rosenberg SA (1994) Cloning of the gene-coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 91:3515
19. Kawasaki KS, Clark SS, Coyne MY, Smith SD, Champlin R, Witte ON, McCormick FP (1988) Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro. Proc Natl Acad Sci USA 85:5698
20. Lanzavecchia A (1995) How can cryptic epitopes trigger autoimmunity? J Exp Med 181:1945
21. Lee C, Sutkowski DM, Sensibar JA, Zelner D, Kim I, Amsel I, Shaw N, Prins GS, Kozlowski JM (1995) Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone. Endocrinology 136:796
22. Lepor H, Ross A, Walsh PC (1982) The influence of hormonal therapy on survival of men with advanced prostatic cancer. J Urol 128:335
23. Lerner SP, Seale-Hawkins C, Carlton CE, Jr., Scardino PT (1991) The risk of dying of prostate cancer in patients with clinically localized disease. J Urol 146:1040
24. Lotze MT, Finn OJ (1990) Recent advances in cellular immunology: implications for immunity to cancer. Immunol Today 11:190
25. Lundak RL, Raidt DJ (1973) Cellular immune response against tumor cells. I. In vitro immunization of allogeneic and syngeneic mouse spleen cell suspensions against DBA mastocytoma cells. Cell Immunol 9:60
26. Maryanski JL, Van Snick J, Cerottini JC, Boon T (1982) Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. III. Clonal analysis of the syngeneic cytolytic T lymphocyte response. Eur J Immunol 12:401
27. McAdam AJ, Felcher A, Woods ML, Pulaski BA, Hutter EK, Frelinger JG, Lord EM (1994) Transfection of transforming growth factor-beta producing tumor EMT6 with interleukin-2 elicits tumor rejection and tumor reactive cytoloxic T-lymphocytes. J Immunother 15:155
28. McAdam AJ, Pulaski BA, Storozynsky E, Yeh KY, Sickel JZ, Frelinger JG, Lord EM (1995) Analysis of the effect of cytokines (interleukins 2, 3, 4, and 6, granulocyte-monocyte colony-stimulating factor, and interferon-gamma) on generation of primary cytotoxic T lymphocytes against a weakly immunogenic tumor. Cell Immunol 165:183
29. McCormack RT, Rittenhouse HG, Finlay JA, Sokoloff RL, Wang TJ, Wolfert RL, Lilja H, Oesterling JE (1995) Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era. Urology 45:729
30. Montgomery BT, Young CY, Bilhartz DL, Andrews PE, Prescott JL, Thompson NE, Tindall DJ (1992) Hormonal regulation of prostate-specific antigen (PSA) glycoprotein in the human prostatic adenocarcinoma cell line, LNCaP. Prostate 21:63
31. Moody DB, Robinson JC, Ewing CM, Lazenby AJ, Isaacs WB (1994) Interleukin-2 transfected prostate cancer cells generate a local antitumor effect in vivo. Prostate 24:244
32. Nanda NK, Sercarz EE (1995) Induction of anti-self-immunity to cure cancer. Cell 82:13
33. Ohashi PS, Ochen S, Buerki K, Pircher H, Ohashi CT, Odermatt B, Malissen B, Zinkernagel RM, Hengartner H (1991) Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 65:305
34. Peehl DM (1995) Prostate specific antigen role and function. Cancer 75 [Suppl]:2021
35. Pulaski BA, McAdam AJ, Hutter EK, Biggar S, Lord EM, Frelinger JG (1993) Interleukin 3 enhances development of tumor-reactive cytotoxic cells by a CD4-dependent mechanism. Cancer Res 53:2112
36. Raghavan D (1988) Non-hormone chemotherapy for prostate cancer: principles of treatment and application to the testing of new drugs. Semin Oncol 15:371
37. Salemi S, Caporossi AP, Boffa L, Longobardi MG, Barnaba V (1995) HIVgp120 activates autoreactive CD4-specific T cell responses by unveiling of hidden CD4 peptides during processing. J Exp Med 181:2253
38. Sanda MG, Ayyagari SR, Jaffee EM, Epstein JI, Clift SL, Cohen LK, Dranoff G, Pardoll DM, Mulligan RC, Simons JW (1994) Demonstration of a rational strategy for human prostate cancer gene therapy. J Urol 151:622
39. Schwartz RH (1993) Immunological tolerance: In: Paul WE (ed) Fundamental immunology, 3rd edn. Raven, New York, p 677
40. Sercarz EE, Lehmann PV, Ametani A, Benichou G, Miller A, Moudgil K (1993) Dominance and crypticity of T cell antigenic determinants. Annu Rev Immunol 11:729
41. Sinha AA, Hagen KA, Sibley RK, Wilson MJ, Limas C, Reddy PK, Blackard CE, Gleason DF (1986) Analysis of fixation effects on immunohistochemical localization of prostatic specific antigen in human prostate. J Urol 136:722
42. Wang RE, Robbins PF, Kawakami Y, Kang XQ, Rosenberg SA (1995) Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J Exp Med 181:799
43. Yang JC, Perry-Lalley D, Rosenberg SA (1990) An improved method for growing murine tumor-infiltrating lymphocytes with in vivo antitumor activity. J Biol Response Mod 9:149
44. Yuhas JM, Pazmino NH, Proctor JO, Toya RE (1974) A direct relationship between immune competence and the subcutaneous growth rate of a malignant murine lung tumor. Cancer Res 34:722